|
Volumn 3, Issue 3, 2002, Pages 249-255
|
Pharmacoeconomics of drug therapy for atopic dermatitis
|
Author keywords
Children; Cost effectiveness; Eczema; Family stress; Immunomodulators; Indirect costs
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIHISTAMINIC AGENT;
AZATHIOPRINE;
CLOBETASOL PROPIONATE;
CORTICOSTEROID;
CYCLOSPORIN A;
EMOLLIENT AGENT;
GAMMA INTERFERON;
GLUCOCORTICOID;
HYDROCORTISONE;
HYDROCORTISONE BUTYRATE;
IMMUNOGLOBULIN;
LACTAM DERIVATIVE;
MACROLACTAM;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PIMECROLIMUS;
PREDNISONE;
PROMETHAZINE;
TACROLIMUS;
UNCLASSIFIED DRUG;
ARTICLE;
ATOPIC DERMATITIS;
BONE MARROW SUPPRESSION;
CAREGIVER;
CHILDHOOD DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
CREAM;
DISEASE SEVERITY;
DISTRESS SYNDROME;
DRUG COST;
DRUG SAFETY;
ENDOCRINE DISEASE;
FAMILY;
GOVERNMENT;
HEALTH CARE COST;
HUMAN;
LONG TERM CARE;
NEPHROTOXICITY;
OINTMENT;
PATIENT MONITORING;
PREVALENCE;
REMISSION;
SKIN DISEASE;
SOCIAL ASPECT;
SUPERINFECTION;
WESTERN HEMISPHERE;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
DERMATITIS, ATOPIC;
DERMATOLOGIC AGENTS;
DRUG COSTS;
HUMANS;
|
EID: 0036192755
PISSN: 14656566
EISSN: None
Source Type: Journal
DOI: 10.1517/14656566.3.3.249 Document Type: Article |
Times cited : (20)
|
References (43)
|